Results 221 to 230 of about 51,615 (305)

Restoration of Autophagy and Apoptosis in Myelodysplastic Syndromes: The Effect of Azacitidine in Disease Pathogenesis. [PDF]

Curr Issues Mol Biol
Tsekoura G, Agathangelidis A, Kontandreopoulou CN, Fasouli ES, Katsantoni E, Pliaka V, Alexopoulos L, Katana E, Papaioannou M, Taktikou G, Strataki ME, Taliouraki A, Mantzourani M, Viniou NA, Diamantopoulos PT, Kollia P.   +15 more
europepmc   +1 more source

Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with ≥5% blasts: An International TP53 Investigators Network (iTiN) study

Cancer, Volume 132, Issue 1, 1 January 2026.
ABSTRACT Background Isolated chromosome 5/5q losses (–5/5q) without TP53 mutations are associated with favorable outcomes in myeloid neoplasms (MN) with <5% blasts. However, the clinical implication of concurrent −5/5q and TP53 aberrations in MN with ≥5% blasts is poorly understood.
Irfan Yasin, Anna Stengel, Haipeng Shao, Amandeep Kaur, Emily F. Mason, Pranav P. Patwardhan, Nathanael G. Bailey, Sharmila Ghosh, Kedar V. Inamdar, Anand A. Patel, Madhavi Pandiri, Jingjing Zhang, Payal Sojitra, Hamza Tariq, Zenggang Pan, Danica Wiredja, Peng Wang, Melissa Y. Tjota, Jeremy P. Segal, Hong Chang, David A. Sallman, Daniel A. Arber, Ayalew Tefferi, Talha Badar, Anamarija M. Perry, Claudia Haferlach, Angela M. Lager, Girish Venkataraman   +27 more
wiley   +1 more source

Treatment of high-risk myelodysplastic syndromes. [PDF]

Haematologica
Kröger N.
europepmc   +1 more source

Hematopoietic effects of tagraxofusp in treatment‐naive patients with blastic plasmacytoid dendritic cell neoplasm

Cancer, Volume 132, Issue 1, 1 January 2026.
Abstract Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic neoplasm that expresses CD123, is often observed in the bone marrow (BM), as well as skin, blood, and viscera. Tagraxofusp, a first‐in‐class CD123‐targeted therapy, is the only drug approved to treat BPDCN.
Marina Konopleva, Naveen Pemmaraju, Kendra L. Sweet, Anthony S. Stein, David A. Rizzieri, Eunice S. Wang, Sumithira Vasu, Todd Rosenblat, Michael Zuurman, Ira Gupta, Andrew A. Lane   +10 more
wiley   +1 more source

Retraction: NAD(P)H: Quinone oxidoreductase 1 deficiency conjoint with marginal vitamin C deficiency causes cigarette smoke induced myelodysplastic syndromes. [PDF]

PLoS One
PLOS One Editors.
europepmc   +1 more source

Venetoclax‐Based Therapy for Early Relapse in Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report and Minireview

Cancer Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Background Refractory/relapsed acute myeloid leukemia (R/R‐AML) typically exhibits resistance to conventional chemotherapy, resulting in a poor overall therapeutic outcome. Salvage allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is the primary treatment option in such patients.
Yufeng Du, Mohammad Arian Hassani, Chunhong Li, Zhijia Zhao, Yikun Liu, Chengtao Zhang, Jinsong Yan   +6 more
wiley   +1 more source

Frailty in Patients With Hematologic Malignancies and Patients Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review

Cancer Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Background Hematopoietic stem cell transplantation (HSCT) is associated with significant morbidity and mortality. Frailty further increases these risks in recipients of HSCT. This systematic review analyzes the extent of frailty in patients with hematologic malignancies and patients undergoing HSCT, and explores the associations between ...
Marit Bakken, Marie Roko Kallager, Marie Hamilton Larsen, Simen A. Steindal, Kristin J. Skaarud   +4 more
wiley   +1 more source

Implications for metabolic disturbances in myelodysplastic syndromes. [PDF]

Semin Hematol
McGraw KL, Larson DR.
europepmc   +1 more source

Pharmacovigilance Insights Into Immune Checkpoint Inhibitor‐Induced Risk of Paraneoplastic Syndrome: A Large‐Scale Real World Study

CNS Neuroscience &Therapeutics, Volume 32, Issue 1, January 2026.
Immune checkpoint inhibitors are associated with rare but severe paraneoplastic syndromes, particularly in lung cancer patients. PS onset shows a bimodal pattern, with increased severity seen in combination therapies like durvalumab plus tremelimumab.
Bufu Tang, Xin Song, Yiting Sun, Juncheng Wan, Wenlu Hu, Yifei Ma, Yihang Lin, Jian Zhang, Yiou Wang, Hongyang Feng, Peng Luo, Dandan Guo, Xudong Qu   +12 more
wiley   +1 more source

<i>PTPN11</i> mutations define a rare but highly adverse subset of myelodysplastic syndromes. [PDF]

Haematologica
Bazinet A, Bataller A, Montalban-Bravo G, Chien K, Sasaki K, Jen WY, Swaminathan M, Kadia T, DiNardo C, Ravandi F, Garcia-Manero G, Kantarjian H.   +11 more
europepmc   +1 more source